Press Releases

Biocartis Partners with Lilly to Explore Biomarker Testing for NSCLC Patients using the Idylla Platform

Biocartis and HiloProbe to Collaborate on Colorectal Cancer Test

Biocartis and APIS Assay Technologies Sign Collaboration to Develop and Commercialise a Breast Cancer Subtyping Test on the Idylla Platform

Biocartis announces the US FDA 510(k) clearance for the Idylla MSI Test

Biocartis announces the launch of the first assay developed with the new Idylla FLEX technology

New Idylla EGFR Study Shows Reduction of Time-to-Treatment by 48% for Lung Cancer Patients

Biocartis Announces Nine Idylla Studies to be Published at Upcoming AMP 2022 Annual Meeting

Biocartis Initiates Commercialization in Europe of HepatoPredict (CE-IVD) Test for Liver Cancer Patients

Biocartis Initiates Commercialization in Europe of SkylineDx’s Innovative Merlin™ Assay (CE-IVD) for Melanoma Patients

Biocartis Obtains ISO 27001 Certification for Information Security Management